series-c-plus
Stage
1
Investors
About
Annexon Biosciences develops complement C1q-targeting therapeutics to treat autoimmune, neurodegenerative, and ophthalmic diseases driven by the classical complement pathway.
Explore Annexon Biosciences's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.